Physician profile
David Lin
NPI 1770650517
$395.19
in general payments reported to CMS, 2019-2025
12 companies · $21.75 in 2025
The $21.75 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $51.12 · 2023: $56.21 · 2025: $21.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.80 | 2019-2020 | |
| Boston Scientific Corporation | $47.11 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.85 | 2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $29.63 | 2019-2020 | |
| Vifor Pharma, INC. | $18.25 | 2019 | |
| Novo Nordisk INC | $11.93 | 2019 | |
| Melinta Therapeutics, LLC | $11.63 | 2019 | |
| Insmed, INC. | $11.60 | 2019 | |
| Shire North American Group INC | $11.43 | 2019 | |
| Angiodynamics, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.